Vaping among ex-smokers in England surged from 2% in 2013 to over 20% in 2024, driven by younger demographics and disposable e-cigarettes, raising questions about health implications and smoking relapse.
Verona inks financing deal worth up to $650M ahead of COPD decision
Verona Pharma has secured up to $650 million to aid the potential launch of its COPD candidate ensifentrine. Under new agreements with Oaktree Capital Management